Literature DB >> 16778800

Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a.

Ralf Gutzmer1, Brigitta Köther, Jörg Zwirner, Dorothea Dijkstra, Rahul Purwar, Miriam Wittmann, Thomas Werfel.   

Abstract

The presence of plasmacytoid dendritic cells (pDC) was recently demonstrated in lesions of inflammatory skin diseases. Since anaphylatoxins or their precursors were also found in such lesions, we investigated a possible interaction between pDC and anaphylatoxins C3a and C5a. pDC precursors isolated from peripheral blood did not express the receptors for C3a and C5a, complement C3a receptor (C3aR) and complement C3a receptor (C5aR). If these pDC precursors were cultured with IL-3, the resultant immature pDC expressed both receptors. Expression of C3aR and C5aR could also be demonstrated on pDC in lesions of cutaneous lupus erythematosus and allergic contact dermatitis. Such pDC were immature since they lacked the expression of the maturation marker CD83. Blood-derived pDC matured with CpG oligonucleotides downregulated the receptors. Immature pDC responded to C3a and C5a (but not C3adesArg) stimulation with increased F-actin polymerization and chemotactic migration. In contrast, interferon alpha production, surface molecule expression, and T-cell stimulatory capacity were not significantly modulated by C3a or C5a. Thus, immature pDC represent another type of antigen-presenting cell that express C3aR and C5aR, and respond to anaphylatoxins with chemotaxis. This might be relevant in the direction of pDC to cutaneous lesions of inflammation, for example, in lupus erythematosus or contact dermatitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778800     DOI: 10.1038/sj.jid.5700416

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  17 in total

1.  Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection.

Authors:  Christopher B Brooke; Alexandra Schäfer; Glenn K Matsushima; Laura J White; Robert E Johnston
Journal:  J Gen Virol       Date:  2011-12-28       Impact factor: 3.891

2.  Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.

Authors:  Eszter Deak; Asha Jayakumar; Ka Wing Cho; Karen Goldsmith-Pestana; Blaise Dondji; John D Lambris; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

Review 3.  Chemokine and chemotactic signals in dendritic cell migration.

Authors:  Laura Tiberio; Annalisa Del Prete; Tiziana Schioppa; Francesca Sozio; Daniela Bosisio; Silvano Sozzani
Journal:  Cell Mol Immunol       Date:  2018-03-21       Impact factor: 11.530

Review 4.  Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

Authors:  Felipe von Glehn; Leonilda M Santos; Konstantin E Balashov
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

Review 5.  Plasmacytoid dendritic cells in HIV infection.

Authors:  Meagan O'Brien; Olivier Manches; Nina Bhardwaj
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

6.  Deficiency of C5aR prolongs renal allograft survival.

Authors:  Qijun Li; Qi Peng; Guolan Xing; Ke Li; Naiyin Wang; Conrad A Farrar; Lucy Meader; Steven H Sacks; Wuding Zhou
Journal:  J Am Soc Nephrol       Date:  2010-07-22       Impact factor: 10.121

7.  Suppression of antibody-mediated arthritis in mice by Fab fragments of the mediating antibodies.

Authors:  S Yoshino; M Sasahara; Pilaiwanwadee Hutamekalin; K Yamaki; N Mizutani; H Kuramoto
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

8.  Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.

Authors:  Sara M Mangsbo; Javier Sanchez; Kerstin Anger; John D Lambris; Kristina Nilsson Ekdahl; Angelica S Loskog; Bo Nilsson; Thomas H Tötterman
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

9.  Complement 5a receptor inhibition improves renal allograft survival.

Authors:  Faikah Gueler; Song Rong; Wilfried Gwinner; Michael Mengel; Verena Bröcker; Sylvia Schön; Tim Friedrich Greten; Heiko Hawlisch; Thomas Polakowski; Karsten Schnatbaum; Jan Menne; Hermann Haller; Nelli Shushakova
Journal:  J Am Soc Nephrol       Date:  2008-08-27       Impact factor: 10.121

Review 10.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.